Chairman and Group CEO, Merck KGaA
Appears in 1 story
Leading his first major acquisition since taking the top job in September 2025
Merck KGaA of Darmstadt, Germany, agreed to buy Bio-Techne, a Minneapolis company that makes the reagents, proteins, and imaging tools researchers use at the lab bench. The price is $73 a share in cash, about $11.3 billion, a 36% premium over the recent trading average.
Updated Jun 25
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
